Our focus ...
Dr. Hassane's laboratory pushes the power of genomics, including pharmacogenomicsTechnologies that enable an understanding of how genetic variation predicts response to therapy. We extend this general definition to include how transcriptional responses predict both drug response and the modulation of drug response. and genome sequencing, to develop new ways of improving cancer treatment by understanding and modulating the genes and gene networks that drive cancer and its response to drugs.
With a major focus on leukemiaA cancer in which blood cells accumulate or grow abnormally and fail to produce functional mature blood cells., we combine laboratory experiments and state-of-the-art genome analytics to address the critical challenges in cancer: overcoming drug resistance, preventing relapseThe re-emergence of cancer following treatment. With acute myeloid leukemia, relapse often occurs within 8 months!, avoiding secondary malignanciesA cancer or "pre-cancer" such as leukemia or myelodysplastic syndrome arising as a result of the treatment another type of cancer., and ablating cancer stem cellsA subpopulation of cells within cancer that resist chemotherapy and can regenerate the tumor..
Our efforts aim to help patients by:
- Developing better drugs and drug combinations that target cancer stem cells.
- Helping physicians make better decisions about what therapies are best for individual patients.